良性甲状腺疾病患者血清IgE、FcεRIα及其抗体水平分析

doi:10.3969/j.issn.1673-8640.2015.05.010

摘要/Abstract

摘要： 目的分析免疫球蛋白(IgE)、FcεRIα及其抗体水平在良性甲状腺疾病患者血清中的表达情况,探讨其与良性甲状腺疾病的相关性。方法收集41例Graves'病(GD)、36例桥本甲状腺炎(HT)和36例甲状腺结节(TN)患者以及60名健康体检者(正常对照组)的临床资料及血清,采用竞争酶联免疫吸附试验(ELISA)检测血清FcεRIα、抗IgE抗体和抗FcεRI抗体水平,采用速率散射比浊法检测血清IgE水平,分析4组间的表达差异并评估其与良性甲状腺疾病的相关性。结果 GD组、HT组及TN组IgE水平与正常对照组比较差异均无统计学意义(P>0.05),而FcεRIα水平和抗IgE抗体水平均明显高于正常对照组(P<0.05);GD组抗FcεRI抗体水平明显高于正常对照组。HT组及TN组血清IgE、FcεRIα、抗IgE抗体及抗FcεRI抗体与甲状腺激素抗体(TRAb)均无相关性。GD组血清FcεRIα与TRAb呈明显负相关(r_s=-0.350,P<0.05),抗IgE抗体和抗FcεRI抗体与TRAb均呈明显正相关(r_s值分别为0.546、0.520,P均<0.05)。结论良性甲状腺疾病患者血清中高表达IgE、FcεRIα及其抗体,并且在GD中与甲状腺抗体有明显相关性,提示此抗体系统可能参与了良性甲状腺疾病的发生、发展。

关键词: 免疫球蛋白E, FcεRIα, 抗免疫球蛋白E抗体, 抗FcεRI抗体, 甲状腺疾病

Abstract: Objective To analyze the expressions of immunoglobulin E (IgE), FcεRIα and their antibodies in serum from patients with benign thyroid diseases and investigate their relationships with benign thyroid diseases. Methods A total of 41 Graves' disease (GD) patients, 36 Hashimoto's thyroiditis (HT) patients, 36 thyroid nodule (TN) patients and 60 healthy subjects were enrolled. The expressions of FcεRIα, anti-IgE antibody and anti-FcεRI antibody were determined by competitive enzyme-linked immunosorbent assay (ELISA), and the level of IgE was determined by rate nephelometry. Their differences in 4 groups and their relationships with benign thyroid diseases were analyzed. Results The levels of IgE in GD, HT and TN groups had no statistical significance compared with that in healthy control group (P>0.05). The serum levels of FcεRIα and anti-IgE antibody in GD, HT and TN groups were higher than that in healthy control group (P<0.05). The level of anti-FcεRI antibody in GD group was higher than that in healthy control group. The relationships of the serum levels of IgE, FcεRIα, anti-IgE antibody and anti-FcεRI antibody with thyroid hormone autoantibody (TRAb) were not observed in HT or TN group, but there was a negative correlation of serum FcεRIα with TRAb (r_s=-0.350, P<0.05), and there was a positive positive correlation of anti-IgE and anti-FcεRI antibodies with TRAb in GD group (r_s=0.546 and 0.520, P<0.05). Conclusions There are high expressions of serum IgE, FcεRIα and their antibodies in patients with benign thyroid diseases and a significant correlation of them with TRAb in GD group. The results suggest that these antibodies may participate in the occurrence and progress of benign thyroid diseases.

Key words: Immunoglobulin E, FcεRIα, Anti-immunoglobulin E, Anti-FcεRI, Thyroid disease

中图分类号:

R446.1

王玉萍, 崔泽林, 蔺丽慧, 王娟, 李佳, 彭霞, 谢国钢, 李莉. 良性甲状腺疾病患者血清IgE、FcεRIα及其抗体水平分析[J]. 检验医学, 2015, 30(5): 450-453.

WANG Yuping, CUI Zelin, LIN Lihui, WANG Juan, LI Jia, PENG Xia, XIE Guogang, LI Li. Analysis on the expressions of serum IgE, FcεRI and their antibodies in patients with benign thyroid diseases[J]. Laboratory Medicine, 2015, 30(5): 450-453.

图/表 3

参考文献 11

[1]	王斌,彭文晖.良性甲状腺疾病手术治疗的临床分析[J].中国医药指南,2014,12(26):198.
[2]	MOSHKELGOSHA S, SO PW, DEASY N, et al.Cutting edge:retrobulbar inflammation,adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves'orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation[J].Endocrinology,2013,154(9):3008-3015.
[3]	中华医学会内分泌学会《中国甲状腺疾病诊治指南》编写组.中国甲状腺疾病诊治指南——甲状腺结节[J].中华内科杂志,2008,47(10):867-968.
[4]	SEGNI M, PUCARELLI I, TRUGLIA S,et al.High prevalence of antinuclear antibodies in children with thyroid autoimmunity[J].J Immunol Res,2014,2014:150239.
[5]	TURKOGLU Z, ZINDANCI I, TURKOGLU O, et al.Skin autoreactivity in Hashimoto's thyroiditis patients without urticaria: autologous serum skin test positivity correlation with thyroid antibodies, sonographical volume and grading[J].Eur J Dermatol,2012,22(3):345-350.
[6]	DOUTRE MS.Chronic urticaria and thyroid auto-immunity[J].Clin Rev Allergy Immunol,2006,30(1):31-37.
[7]	PLATZER B, RUITER F, VAN DER MEE J, et al.Soluble IgE receptors-elements of the IgE network[J].Immunol Lett,2011,141(1):36-44.
[8]	MOLNÉR I. What is the role of allergic sensitization in Graves' disease[J].Orv Hetil,2007,148(29):1347-1352.
[9]	MARONE G,SPADARO G,PALUMBO C,et al.The anti-IgE/anti-Fcepsilon Rlalpha autoantibody network in allergic and autoimmune diseases[J].Clin Exp Allergy,1999,29(1):17-27.
[10]	MACNEIL AJ, YANG YJ, LIN TJ.MAPK kinase 3 specifically regulates Fc epsilonRI-mediated IL-4 production by mast cells[J]. J Immunol,2011,187(6):3374-3382.
[11]	SUZUKI R, LEACH S, LIU W,et al.Molecular editing of cellular responses by the high-affinity receptor for IgE[J].Science,2014,343(6174):1021-1025.

组别	FT3(pmol/L)	FT4(pmol/L)	TT3(nmol/L)	TT4(nmol/L)	TSH(μIU/mL)
GD组	14.6(7.7,29.1)^*	50.2(19.9,83.1)^*	4.9(2.0,7.7)^*	212.8(126.9,283.0)^*	0.04(0.01,0.09)^*
HT组	4.8(4.2,11.9)	19.4(15.7,32.9)^*	1.6(1.3,2.5)	115.5(94.8,155.6)	2.10(0.04,8.80)
TN组	4.4(4.2,5.0)	17.3(15.0,19.7)	1.4(1.2,1.6)	102.7(91.8,125.8)	1.80(1.10,3.30)
正常对照组	4.5(4.0,5.0)	16.6(15.4,19.9)	1.5(1.2,1.6)	107.3(91.9,126.7)	1.84(1.28,2.47)
组别	rT3(nmol/L)	Tg(ng/mL)	TPOAb(IU/mL)	TRAb(IU/L)	A-TG(IU/mL)
GD组	1.6(0.8,2.3)^*	20.0(16.7,28.8)^*	87.5(16.2,335.5)^*	7.2(3.3,19.4)^*	55.0(25.0,511.0)^*
HT组	1.0(0.9,1.2)^*	19.7(15.0,22.8)^*	275.3(90.2,561.3)^*	0.6(0.3,13.4)^*	633.4(254.0,1 219.0)^*
TN组	0.7(0.6,0.9)	8.4(7.3,12.3)	8.5(5.0,13.2)	0.5(0.3,0.7)	12.8(10.0,27.3)
正常对照组	0.7(0.6,0.8)	7.5(6.4,8.6)	7.7(5.4,11.8)	0.4(0.3,0.6)	11.0(10.0,25.7)

组别	FT3(pmol/L)	FT4(pmol/L)	TT3(nmol/L)	TT4(nmol/L)	TSH(μIU/mL)
GD组	14.6(7.7,29.1)^*	50.2(19.9,83.1)^*	4.9(2.0,7.7)^*	212.8(126.9,283.0)^*	0.04(0.01,0.09)^*
HT组	4.8(4.2,11.9)	19.4(15.7,32.9)^*	1.6(1.3,2.5)	115.5(94.8,155.6)	2.10(0.04,8.80)
TN组	4.4(4.2,5.0)	17.3(15.0,19.7)	1.4(1.2,1.6)	102.7(91.8,125.8)	1.80(1.10,3.30)
正常对照组	4.5(4.0,5.0)	16.6(15.4,19.9)	1.5(1.2,1.6)	107.3(91.9,126.7)	1.84(1.28,2.47)
组别	rT3(nmol/L)	Tg(ng/mL)	TPOAb(IU/mL)	TRAb(IU/L)	A-TG(IU/mL)
GD组	1.6(0.8,2.3)^*	20.0(16.7,28.8)^*	87.5(16.2,335.5)^*	7.2(3.3,19.4)^*	55.0(25.0,511.0)^*
HT组	1.0(0.9,1.2)^*	19.7(15.0,22.8)^*	275.3(90.2,561.3)^*	0.6(0.3,13.4)^*	633.4(254.0,1 219.0)^*
TN组	0.7(0.6,0.9)	8.4(7.3,12.3)	8.5(5.0,13.2)	0.5(0.3,0.7)	12.8(10.0,27.3)
正常对照组	0.7(0.6,0.8)	7.5(6.4,8.6)	7.7(5.4,11.8)	0.4(0.3,0.6)	11.0(10.0,25.7)

组别	IgE(IU/mL)	FcεRIα(μg/mL)	抗IgE抗体(μg/mL)	抗FcεRI抗体(μg/mL)
GD组	48.3(24.0,219.0)	6.7(4.2,9.9)^*	2.4(1.5,4.9)^*	61.8(42.8,104.0)^*
HT组	44.0(19.4,91.4)	5.5(3.3,8.2)^*	1.4(0.8,3.1)^*	41.6(27.6,65.7)
TN组	44.7(20.9,99.0)	7.7(5.2,9.9)^*	1.5(1.0,1.9)^*	43.5(33.0,52.5)
正常对照组	31.8(17.5,95.0)	2.8(1.7,6.2)	1.0(0.8,1.2)	36.7(29.6,44.4)

组别	IgE(IU/mL)	FcεRIα(μg/mL)	抗IgE抗体(μg/mL)	抗FcεRI抗体(μg/mL)
GD组	48.3(24.0,219.0)	6.7(4.2,9.9)^*	2.4(1.5,4.9)^*	61.8(42.8,104.0)^*
HT组	44.0(19.4,91.4)	5.5(3.3,8.2)^*	1.4(0.8,3.1)^*	41.6(27.6,65.7)
TN组	44.7(20.9,99.0)	7.7(5.2,9.9)^*	1.5(1.0,1.9)^*	43.5(33.0,52.5)
正常对照组	31.8(17.5,95.0)	2.8(1.7,6.2)	1.0(0.8,1.2)	36.7(29.6,44.4)

项目	TPOAb	A-TG	TRAb
IgE	0.177	-0.178	0.229
FcεRIα	-0.024	-0.350	0.052
抗IgE抗体	-0.018	-0.120	0.546
抗FcεRI抗体	0.125	-0.018	0.520